Quest Partners LLC Sells 3,421 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Quest Partners LLC decreased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 20.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,593 shares of the company’s stock after selling 3,421 shares during the quarter. Quest Partners LLC’s holdings in 10x Genomics were worth $307,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in TXG. Vanguard Group Inc. grew its position in shares of 10x Genomics by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 9,101,536 shares of the company’s stock worth $341,581,000 after buying an additional 90,204 shares in the last quarter. Advisors Asset Management Inc. grew its position in shares of 10x Genomics by 27.3% during the 1st quarter. Advisors Asset Management Inc. now owns 25,228 shares of the company’s stock worth $947,000 after buying an additional 5,406 shares in the last quarter. Lazard Asset Management LLC grew its position in shares of 10x Genomics by 23.1% during the 1st quarter. Lazard Asset Management LLC now owns 74,540 shares of the company’s stock worth $2,797,000 after buying an additional 13,972 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of 10x Genomics by 17.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,657,227 shares of the company’s stock worth $137,257,000 after buying an additional 553,053 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in 10x Genomics during the first quarter valued at about $3,647,000. Institutional investors own 84.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TXG shares. The Goldman Sachs Group dropped their price objective on 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a research report on Wednesday, October 30th. Stephens reaffirmed an “overweight” rating and set a $30.00 price objective on shares of 10x Genomics in a research report on Thursday, October 10th. Barclays dropped their price objective on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Leerink Partners started coverage on 10x Genomics in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $35.00 price objective on the stock. Finally, Canaccord Genuity Group dropped their price objective on 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, 10x Genomics currently has an average rating of “Moderate Buy” and a consensus target price of $29.19.

10x Genomics Stock Up 6.9 %

Shares of NASDAQ:TXG opened at $15.30 on Tuesday. 10x Genomics, Inc. has a 52-week low of $12.95 and a 52-week high of $57.90. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -10.00 and a beta of 1.87. The business has a 50-day moving average price of $17.44 and a 200-day moving average price of $19.81.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04. The firm had revenue of $151.65 million for the quarter, compared to analyst estimates of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. 10x Genomics’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period last year, the company earned ($0.51) earnings per share. As a group, equities analysts anticipate that 10x Genomics, Inc. will post -1.4 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.